查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950525

肽類藥物偶聯物CDMO服務市場：按營運規模、服務產品、胜肽類型、治療領域和最終用戶分類，全球預測，2026-2032年

Peptide-Drug Conjugates CDMO Service Market by Scale Of Operation, Service Offering, Peptide Type, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年肽類藥物偶聯物 CDMO 服務市值為 3.4567 億美元，預計到 2026 年將成長至 3.5795 億美元，預計到 2032 年將達到 4.8021 億美元，複合年成長率為 4.80%。

關鍵市場統計數據
基準年 2025 3.4567億美元
預計年份：2026年 3.5795億美元
預測年份 2032 4.8021億美元
複合年成長率 (%) 4.80%

全面概述胜肽類藥物偶聯物CDMO服務，重點介紹其技術深度、營運準備以及對開發商的戰略價值促進因素。

肽類藥物偶聯物 (PDC) 的 CDMO 行業概況需要一份重點突出、清晰闡述當前能力、價值提案以及面向製藥和生物技術相關人員的戰略重點的概要。本執行摘要首先重點介紹 CDMO 合作夥伴如何實現複雜的有效載荷-連接子-肽整合，以及從肽合成到偶聯、製劑和分析表徵的一體化服務為何對縮短臨床開發週期和提高產品品質至關重要。

連接子化學、胜肽合成、分析自動化和監管要求的創新如何從根本上重塑CDMO夥伴關係模式

近期發生的變革性變化正在重塑胜肽-藥物偶聯物的研發、生產和臨床應用方式。連接子化學和可裂解設計方面的進步提高了偶聯物的治療精準度，迫使合約研發生產機構（CDMO）採用專門的偶聯平台和更嚴格的分析控制。同時，胜肽合成調查方法的改進，包括固相和液相化學的最佳化，正在縮短合成週期，降低雜質含量，並促進藥物研發團隊與生產合作夥伴之間更緊密的合作。

評估 2025 年關稅如何促使 CDMO 重組其採購業務、考慮近岸外包並加強其供應鏈韌性。

2025年美國關稅的累積影響已對胜肽類藥物偶聯物生態系統中合約研發生產機構（CDMO）的營運和供應鏈經濟造成了顯著壓力。依賴進口的投入品，例如特種試劑、某些層析法樹脂和分析儀器零件，其到岸成本均增加，迫使契約製造及其客戶重新評估籌資策略和供應商選擇標準。海關合規方面的行政複雜性和物流交貨前置作業時間的變化進一步加劇了這些投入成本壓力，迫使營運團隊採用更動態的庫存管理和採購慣例。

將治療需求、開發規模、服務能力、胜肽化學類型和最終用戶期望與CDMO選擇標準連結起來的詳細細分分析

全面的細分分析揭示了不同治療領域、企業規模、服務產品、胜肽類型和最終用戶類別在服務需求和技術期望方面的細微差異。從治療領域來看，開發人員主要關注以下幾個方面：心血管領域，細分為動脈粥樣硬化和心臟衰竭，並具有特定的藥物動力學和穩定性要求；免疫學領域，涵蓋自體免疫疾病和發炎性疾病，重點在於降低免疫抗原性；傳染病感染疾病，涵蓋細菌和病毒感染疾病，製劑和遞送固態腫瘤骨髓惡性腫瘤影響偶聯物的標靶化；

比較和評估區域監管成熟度、製造能力和供應鏈韌性，以塑造跨區域CDMO服務採購。

區域趨勢對胜肽類藥物偶聯物價值鏈上的服務可用性、監管參與和成本結構均有顯著影響。在美洲，強大的臨床試驗生態系統和大型製藥企業聚集地為先進的生產能力和監管經驗提供了支撐，而物流基礎設施和密集的供應商網路則有助於快速擴大生產規模和建立臨床供應體系。儘管對本地生產能力和人才培養的過渡性投資持續增強該地區的韌性，但成本壓力和關稅因素正在影響企業選擇採購特殊投入品的地點。

CDMO企業的定位和夥伴關係趨勢揭示了其在能力投資、策略性收購和人才主導競爭優勢方面的努力。

胜肽類藥物偶聯物CDMO領域的競爭動態呈現出策略定位的頻譜，從垂直整合型供應商到高度專業化的利基市場參與者，不一而足。領先的服務供應商透過投資平台技術來降低偶聯異質性，透過強大的分析套件提供深入的表徵能力，並透過連接藥物發現和生產的製程開發團隊來實現差異化。同時，小規模的專業公司則透過提供敏捷性、客製化的開發路徑和緊密的合作模式來參與競爭，從而加快新型偶聯物首次人體給藥的進程。

針對CDMO和申辦方，可採取具有重大影響的營運和策略步驟，以增強偶聯物專案的可生產性、監管準備和供應鏈韌性。

產業領導者應採取一系列切實可行的措施，增強自身韌性，加速創新，並在胜肽類藥物偶聯物的研發和生產領域中獲得戰略優勢。優先投資於模組化、靈活的生產平台，以實現從發現階段合成到臨床和商業化生產的快速過渡，從而降低技術風險並加速臨床試驗進程。同時，應拓展內部分析能力和自動化表徵工作流程，以確保雜質譜分析和批次間可比性。這將簡化與監管機構的溝通，並有助於加快核准。

結合專家訪談、文獻綜述、監管框架分析和情境壓力測試的系統性調查方法，能夠提供實際的見解。

本執行摘要的調查方法結合了定性和定量方法，以確保獲得可靠的三角驗證結果。主要研究包括對高級研發主管、採購專業人員、生產主管以及直接管理胜肽類藥物偶聯物專案的偶聯化學和分析開發專家進行結構化訪談和有針對性的討論。這有助於深入了解不同治療領域和研發階段所面臨的技術挑戰、夥伴關係標準和營運限制。

整合技術、業務和策略考量，指導CDMO合作決策，並推動偶聯療法的成功研發。

總之，胜肽類藥物偶聯物（PDC）CDMO環境正處於技術複雜性不斷提高和商業性壓力不斷演變的雙重挑戰之下。偶聯化學和胜肽合成技術的進步提高了生產合作夥伴的技術門檻，而貿易動態的變化和區域投資趨勢正在重塑籌資策略。這些因素共同造就了這樣一個市場格局：技術專長、監管能力和供應鏈韌性將決定夥伴關係的成敗。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 胜肽類藥物偶聯物CDMO服務市場（依營運規模分類）

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業的
    • 大規模生產
    • 小規模生產
  • 藥物發現階段
  • 飛行員

9. 胜肽類藥物偶聯物CDMO服務市場（依服務類型分類）

  • 分析服務
    • 特徵描述
    • 發布測試
    • 穩定性測試
  • 加入
    • 可裂解連接子
    • 不可切割的連接子
  • 配方
    • 液體
    • 冷凍乾燥
  • 胜肽合成
    • 液相
    • 固相
  • 製程開發
    • 下游工藝
    • 上游工程

10. 依胜肽類型分類的胜肽類藥物偶聯物CDMO服務市場

  • 圓
  • 線性類型
  • 合格類型
  • 胜肽類似物

11. 肽類藥物偶聯物CDMO服務市場（依治療領域分類）

  • 循環系統
    • 動脈粥狀硬化
    • 心臟衰竭
  • 免疫學
    • 自體免疫疾病
    • 發炎性疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤

12. 依最終用戶分類的胜肽類藥物偶聯物CDMO服務市場

  • 學術機構
  • 生物技術
  • 合約研究機構
  • 政府
  • 製藥公司

13. 肽類藥物偶聯物CDMO服務市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 胜肽類藥物偶聯物CDMO服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國肽類藥物偶聯物CDMO服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國胜肽類藥物偶聯物CDMO服務市場

17. 中國：胜肽類藥物偶聯物CDMO服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aobious, Inc.
  • Asymchem, Inc.
  • Bachem Holding AG
  • BioDuro, Inc.
  • Biopeptek, Inc.
  • Bio-Synthesis Inc.
  • BOC Sciences Ltd.
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Creative Peptides, Inc.
  • Evotec SE
  • GenScript Biotech Corporation
  • JPT Peptide Technologies GmbH
  • Lonza Group AG
  • Peptide International, Inc.
  • Piramal Pharma Solutions
  • Polypeptide Group GmbH
  • Recipharm AB
  • ScinoPharm Taiwan Ltd.
  • SN Biopharm Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • USV Private Limited
  • WuXi AppTec Co., Ltd.
  • Xinbang Pharma Co., Ltd.
Product Code: MRR-4F7A6D4FD8BC

The Peptide-Drug Conjugates CDMO Service Market was valued at USD 345.67 million in 2025 and is projected to grow to USD 357.95 million in 2026, with a CAGR of 4.80%, reaching USD 480.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 345.67 million
Estimated Year [2026] USD 357.95 million
Forecast Year [2032] USD 480.21 million
CAGR (%) 4.80%

Comprehensive orientation to peptide-drug conjugates CDMO services highlighting technical depth, operational readiness, and strategic value drivers for developers

The peptide-drug conjugates CDMO landscape requires a focused introduction that frames current capabilities, value propositions, and strategic priorities for stakeholders across pharmaceutical and biotechnology sectors. This executive summary initiates the narrative by clarifying how CDMO partners enable complex payload-linker-peptide integrations and why integrated service offerings from peptide synthesis through conjugation, formulation, and analytical characterization matter for accelerating clinical timelines and enhancing product quality.

By situating CDMO capabilities against the evolving technical demands of conjugate design, this section highlights the practical intersections between scientific rigor and operational execution. It underscores the importance of end-to-end process control, risk-managed supply chains, and flexible manufacturing paradigms that allow developers to translate discovery-stage sequences into clinical-grade materials. This orientation sets expectations for the subsequent analysis and positions readers to evaluate CDMO selection criteria through the lenses of technical competence, regulatory readiness, and commercial scalability.

How innovations in linker chemistry, peptide synthesis, analytical automation, and regulatory expectations are fundamentally reshaping CDMO partnership models

The recent period has produced transformative shifts that reshape how peptide-drug conjugates are developed, manufactured, and brought to clinic. Advances in linker chemistry and cleavable designs have increased the therapeutic precision of conjugates, prompting CDMOs to incorporate specialized conjugation platforms and tighter analytical controls. Concurrently, improvements in peptide synthesis methodologies, including optimized solid-phase and liquid-phase chemistries, have shortened synthesis cycles and reduced impurity profiles, encouraging closer collaboration between discovery teams and manufacturing partners.

Moreover, data-driven integration and automation have permeated analytical workflows, enabling higher-throughput characterization and more reliable stability assessments. Regulatory expectations have evolved in parallel, with agencies emphasizing robust characterization of conjugation heterogeneity, impurity control strategies, and reagent traceability. As a result, CDMOs are shifting from purely transactional service providers to strategic partners offering process development, regulatory support, and lifecycle management. Finally, the industry's risk management posture has matured; developers increasingly prioritize supply chain resilience and multi-sourcing strategies, which drives demand for geographically diversified manufacturing footprints and stronger contractual alignment between innovators and service providers.

Assessing how 2025 tariff measures prompted procurement realignment, nearshoring considerations, and increased supply chain resilience efforts in CDMO operations

The cumulative impact of United States tariff measures enacted in 2025 has exerted measurable pressure on CDMO operations and supply chain economics across the peptide-drug conjugate ecosystem. Import-dependent inputs such as specialized reagents, certain chromatography resins, and analytic instrumentation components experienced increased landed costs, prompting contract manufacturers and their clients to reassess procurement strategies and supplier selection criteria. These input cost pressures were compounded by administrative complexity in customs compliance and shifts in logistical lead times, which required operational teams to adopt more dynamic inventory and procurement practices.

In response, many organizations accelerated supplier qualification programs in alternative jurisdictions and pursued renegotiated supplier contracts to stabilize pricing and availability. Nearshoring and regional capacity expansion became more attractive where tariff differentials threatened margins or schedule certainty, and some CDMOs prioritized in-house vertical capabilities to reduce exposure to tariff-sensitive external vendors. Importantly, the tariff environment pushed cross-functional teams to enhance scenario planning, stress-test supply chains, and incorporate tariff contingency clauses into master service agreements, thereby improving resilience and clarifying cost pass-through mechanisms between service providers and sponsors.

Granular segmentation analysis linking therapeutic needs, development scale, service capabilities, peptide chemotypes, and end-user expectations to CDMO selection criteria

A careful segmentation lens reveals nuanced service requirements and technical expectations across therapeutic areas, scale of operation, service offering, peptide type, and end-user categories. When viewed through the therapeutic area dimension, developers focus on Cardiovascular applications that break down into Atherosclerosis and Heart Failure needs with specific pharmacokinetic and stability demands; Immunology priorities that span Autoimmune Diseases and Inflammatory Disorders with emphasis on immunogenicity mitigation; Infectious Disease vectors that cover Bacterial Infection and Viral Infection where formulation and delivery concerns influence conjugate design; and Oncology indications that span Hematological Malignancies and Solid Tumors requiring tailored payload potency and tumor-targeting strategies.

Considering scale of operation, clinical development stages impose different CDMO expectations: Discovery and preclinical research demand rapid iterative synthesis and agile conjugation workflows; early-phase Clinical work across Phase I through Phase III requires scalable process development and stringent analytical release testing; Pilot runs test manufacturability and process robustness; and Commercial production focuses on reproducible large-scale manufacturing while also accommodating small-scale specialized batches. In terms of service offering, comprehensive engagements typically integrate peptide synthesis-whether via liquid-phase or solid-phase techniques-conjugation methods utilizing cleavable or noncleavable linkers, formulation approaches that select between liquid and lyophilized formats, process development spanning upstream and downstream operations, and detailed analytical services covering characterization, release testing, and stability testing. The peptide type under consideration-cyclic, linear, modified, or peptidomimetics-influences synthetic route complexity, impurity profiles, and conjugation site selection, thereby shaping the selection of CDMOs with relevant technical experience. Finally, end users range from academic groups and biotechnology firms to contract research organizations, government entities, and pharmaceutical companies; each cohort presents distinct procurement cycles, risk tolerances, and collaboration models that CDMOs must address through tailored service agreements and client engagement frameworks.

Comparative regional evaluation of regulatory maturity, manufacturing capacity, and supply chain resilience shaping CDMO service sourcing across geographies

Regional dynamics materially affect service availability, regulatory interactions, and cost structures across the peptide-drug conjugate value chain. In the Americas, strong clinical trial ecosystems and a concentration of large pharmaceutical sponsors support advanced manufacturing capabilities and regulatory experience, while logistics infrastructure and a dense supplier base enable responsive scale-up and fast clinical supply deployment. Transitional investments in local capacity and workforce development continue to strengthen regional resilience, although cost pressures and tariff considerations influence where sponsors elect to source specialized inputs.

The Europe, Middle East & Africa landscape blends mature regulatory frameworks in Western Europe with emerging manufacturing clusters in select EMEA hubs; firms operating here benefit from established analytical standards and cross-border talent pools, yet they must navigate heterogeneous regulatory pathways and variable reimbursement contexts. In Asia-Pacific, the combination of rapid manufacturing capacity expansion, increasingly sophisticated biotech sectors, and competitive cost structures positions the region as a critical source of both commodity and specialized CDMO services. However, clients must weigh regional regulatory differences, intellectual property considerations, and quality oversight mechanisms when selecting partners. Across regions, the interplay of regulatory expectations, supply chain resilience, and cost structures determines how sponsors and CDMOs prioritize investment and operational partnerships.

Corporate positioning and partnership dynamics among CDMOs revealing capability investments, strategic acquisitions, and talent-driven competitive advantages

Competitive dynamics among companies in the peptide-drug conjugate CDMO space reveal a spectrum of strategic positioning from vertically integrated providers to highly specialized niche players. Leading service providers differentiate through investments in platform technologies that reduce conjugation heterogeneity, robust analytical suites that provide deep characterization capabilities, and process development teams that bridge discovery and manufacturing. At the same time, smaller specialist firms compete by offering agility, bespoke development pathways, and close collaborative models that can accelerate first-in-human timelines for novel conjugates.

Partnership activity has intensified as sponsors seek to de-risk development paths and secure capacity. M&A and strategic alliances frequently target capabilities such as advanced peptide synthesis platforms, enhanced conjugation chemistries, or in-house analytics that address specific regulatory challenges. Talent acquisition remains a differentiator, with companies that cultivate cross-disciplinary expertise-combining synthetic chemistry, conjugation science, and bioprocess engineering-better positioned to respond to complex client needs. Finally, operational excellence in quality systems, regulatory submissions support, and supply chain transparency informs buyer choice and underpins long-term commercial relationships.

High-impact operational and strategic steps for CDMOs and sponsors to enhance manufacturability, regulatory readiness, and supply chain resilience in conjugate programs

Industry leaders should adopt a set of actionable measures to strengthen resilience, accelerate innovation, and capture strategic advantage in peptide-drug conjugates development and manufacturing. Prioritize investment in modular and flexible manufacturing platforms that allow rapid transitions between discovery-scale synthesis and clinical or commercial production, thereby reducing technical risk and shortening go-to-clinic timelines. Simultaneously, expand in-house analytical capabilities and automated characterization workflows to ensure robust impurity profiling and batch-to-batch comparability, which simplifies regulatory interactions and supports expedited approvals.

Furthermore, implement diversified supplier strategies and regional redundancy for tariff-sensitive inputs to guard against geopolitical and trade disruptions. Establish collaborative R&D models with sponsors that embed process development teams early in the discovery phase to enable manufacturability-by-design approaches. Strengthen contractual frameworks to include clear provisions for contingency sourcing, cost pass-through, and shared risk during capacity constraints. Finally, invest in workforce development programs that create cross-functional teams capable of integrating peptide chemistry, conjugation science, and downstream processing, together with data infrastructure that supports knowledge capture, predictive analytics, and continuous improvement initiatives.

Methodical research approach combining expert interviews, literature synthesis, regulatory mapping, and scenario-based stress testing to deliver actionable insights

The research methodology underpinning this executive summary combined qualitative and quantitative approaches to ensure robust, triangulated insights. Primary research comprised structured interviews and targeted discussions with senior R&D leaders, procurement professionals, and manufacturing executives who directly manage peptide-drug conjugate programs, together with subject-matter experts in conjugation chemistry and analytical development. These engagements provided contextual understanding of technical pain points, partnership criteria, and operational constraints observed across therapeutic areas and development stages.

Secondary research involved systematic review of scientific literature, regulatory guidance, patent landscapes, and publicly available corporate disclosures to map technological trajectories and regulatory expectations. Data synthesis employed cross-validation techniques to reconcile practitioner perspectives with documented precedents and technical performance indicators. The analysis also incorporated scenario-based stress testing-examining tariff impacts, supply chain disruptions, and capacity constraints-to inform resilience recommendations. Quality control included peer review by domain experts and consistency checks to ensure clarity, reproducibility, and actionable relevance for decision-makers.

Synthesis of technical, operational, and strategic imperatives guiding CDMO engagement decisions and enabling reliable advancement of conjugate therapeutics

In conclusion, the peptide-drug conjugate CDMO landscape stands at the intersection of deepening technical complexity and evolving commercial pressures. Advances in conjugation chemistry and peptide synthesis have elevated the technical bar for manufacturing partners, while shifting trade dynamics and regional investments have reshaped sourcing strategies. Together, these forces drive a market environment where technical competence, regulatory acumen, and supply chain resilience determine successful partnerships.

Decision-makers should integrate the segmentation, regional, and operational insights presented here to align CDMO selection and investment strategies with program-specific needs. By proactively addressing manufacturing scalability, analytical depth, and contractual clarity, sponsors and service providers can reduce development risk and improve the likelihood of timely clinical progression. The path forward favors collaborative models that integrate early process development, diversify supply options, and continuously invest in capabilities that translate scientific promise into reliable, compliant therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peptide-Drug Conjugates CDMO Service Market, by Scale Of Operation

  • 8.1. Clinical
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Commercial
    • 8.2.1. Large Scale Manufacturing
    • 8.2.2. Small Scale Manufacturing
  • 8.3. Discovery
  • 8.4. Pilot

9. Peptide-Drug Conjugates CDMO Service Market, by Service Offering

  • 9.1. Analytical Services
    • 9.1.1. Characterization
    • 9.1.2. Release Testing
    • 9.1.3. Stability Testing
  • 9.2. Conjugation
    • 9.2.1. Cleavable Linkers
    • 9.2.2. Noncleavable Linkers
  • 9.3. Formulation
    • 9.3.1. Liquid
    • 9.3.2. Lyophilized
  • 9.4. Peptide Synthesis
    • 9.4.1. Liquid Phase
    • 9.4.2. Solid Phase
  • 9.5. Process Development
    • 9.5.1. Downstream
    • 9.5.2. Upstream

10. Peptide-Drug Conjugates CDMO Service Market, by Peptide Type

  • 10.1. Cyclic
  • 10.2. Linear
  • 10.3. Modified
  • 10.4. Peptidomimetics

11. Peptide-Drug Conjugates CDMO Service Market, by Therapeutic Area

  • 11.1. Cardiovascular
    • 11.1.1. Atherosclerosis
    • 11.1.2. Heart Failure
  • 11.2. Immunology
    • 11.2.1. Autoimmune Diseases
    • 11.2.2. Inflammatory Disorders
  • 11.3. Infectious Disease
    • 11.3.1. Bacterial Infection
    • 11.3.2. Viral Infection
  • 11.4. Oncology
    • 11.4.1. Hematological Malignancies
    • 11.4.2. Solid Tumors

12. Peptide-Drug Conjugates CDMO Service Market, by End User

  • 12.1. Academic
  • 12.2. Biotechnology
  • 12.3. Contract Research Organization
  • 12.4. Government
  • 12.5. Pharmaceutical

13. Peptide-Drug Conjugates CDMO Service Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Peptide-Drug Conjugates CDMO Service Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Peptide-Drug Conjugates CDMO Service Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Peptide-Drug Conjugates CDMO Service Market

17. China Peptide-Drug Conjugates CDMO Service Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aobious, Inc.
  • 18.6. Asymchem, Inc.
  • 18.7. Bachem Holding AG
  • 18.8. BioDuro, Inc.
  • 18.9. Biopeptek, Inc.
  • 18.10. Bio-Synthesis Inc.
  • 18.11. BOC Sciences Ltd.
  • 18.12. Catalent, Inc.
  • 18.13. CordenPharma International GmbH
  • 18.14. Creative Peptides, Inc.
  • 18.15. Evotec SE
  • 18.16. GenScript Biotech Corporation
  • 18.17. JPT Peptide Technologies GmbH
  • 18.18. Lonza Group AG
  • 18.19. Peptide International, Inc.
  • 18.20. Piramal Pharma Solutions
  • 18.21. Polypeptide Group GmbH
  • 18.22. Recipharm AB
  • 18.23. ScinoPharm Taiwan Ltd.
  • 18.24. SN Biopharm Co., Ltd.
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. USV Private Limited
  • 18.27. WuXi AppTec Co., Ltd.
  • 18.28. Xinbang Pharma Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LARGE SCALE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SMALL SCALE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PILOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CHARACTERIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY RELEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLEAVABLE LINKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY NONCLEAVABLE LINKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LIQUID PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CYCLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDOMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFLAMMATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BACTERIAL INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY VIRAL INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ACADEMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY GOVERNMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COMMERCIAL, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ANALYTICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CONJUGATION, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY PEPTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MARKET SIZE, BY SCALE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC PEPTIDE-DRUG CONJUGATES CDMO SERVICE MA